(Q37820047)

23 August 2017

1 reference

title

New pathophysiological insights and treatment of ANCA-associated vasculitis (English)

1 reference

Jan Willem Cohen Tervaert

23 August 2017

1 reference

series ordinal

4

object named as

Jan Willem Cohen Tervaert

1 reference

23 August 2017

Benjamin Wilde

1

1 reference

23 August 2017

Pieter van Paassen

series ordinal

2

1 reference

23 August 2017

Oliver Witzke

series ordinal

3

1 reference

23 August 2017

language of work or name

English

0 references

publication date

8 December 2010

1 reference

23 August 2017

1 reference

23 August 2017

volume

79

1 reference

23 August 2017

issue

6

1 reference

23 August 2017

page(s)

599-612

1 reference

Anti-neutrophil cytoplasmic antibodies: current diagnostic and pathophysiological potential

23 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1038%2FKI.2010.472

7 January 2021

Nomenclature of systemic vasculitides. Proposal of an international consensus conference

1 reference

https://api.crossref.org/works/10.1038%2FKI.2010.472

7 January 2021

Illustrated histopathologic classification criteria for selected vasculitis syndromes. American College of Rheumatology Subcommittee on Classification of Vasculitis

1 reference

https://api.crossref.org/works/10.1038%2FKI.2010.472

7 January 2021

Autoantibodies against myeloid lysosomal enzymes in crescentic glomerulonephritis

1 reference

https://api.crossref.org/works/10.1038%2FKI.2010.472

7 January 2021

The American College of Rheumatology 1990 criteria for the classification of churg-strauss syndrome (allergic granulomatosis and angiitis)

1 reference

https://api.crossref.org/works/10.1038%2FKI.2010.472

7 January 2021

The American College of Rheumatology 1990 criteria for the classification of Wegener's granulomatosis

1 reference

https://api.crossref.org/works/10.1038%2FKI.2010.472

7 January 2021

Detection of autoantibodies against myeloid lysosomal enzymes: A useful adjunct to classification of patients with biopsy-proven necrotizing arteritis

1 reference

https://api.crossref.org/works/10.1038%2FKI.2010.472

7 January 2021

Anti-neutrophil cytoplasmic autoantibodies induce neutrophils to degranulate and produce oxygen radicals in vitro

1 reference

https://api.crossref.org/works/10.1038%2FKI.2010.472

7 January 2021

Mechanisms of vasculitis: how pauci-immune is ANCA-associated renal vasculitis?

1 reference

https://api.crossref.org/works/10.1038%2FKI.2010.472

7 January 2021

Proteinase 3: A cofactor for the binding of antineutrophil cytoplasm antibodies (ANCA) to endothelial cells?

1 reference

https://api.crossref.org/works/10.1038%2FKI.2010.472

7 January 2021

Anti-Neutrophil Cytoplasmic Antibody Pathogenesis in Small-Vessel Vasculitis

1 reference

https://api.crossref.org/works/10.1038%2FKI.2010.472

7 January 2021

Constitutive membrane expression of proteinase 3 (PR3) and neutrophil activation by anti-PR3 antibodies

1 reference

https://api.crossref.org/works/10.1038%2FKI.2010.472

7 January 2021

The activation of the neutrophil respiratory burst by anti-neutrophil cytoplasm autoantibody (ANCA) from patients with systemic vasculitis requires tyrosine kinases and protein kinase C activation

1 reference

https://api.crossref.org/works/10.1038%2FKI.2010.472

7 January 2021

Activated neutrophils express proteinase 3 on their plasma membrane in vitro and in vivo

1 reference

https://api.crossref.org/works/10.1038%2FKI.2010.472

7 January 2021

Pathophysiology of ANCA-associated glomerulonephritis

1 reference

https://api.crossref.org/works/10.1038%2FKI.2010.472

7 January 2021

Leucocyte membrane expression of proteinase 3 correlates with disease activity in patients with Wegener's granulomatosis

1 reference

https://api.crossref.org/works/10.1038%2FKI.2010.472

7 January 2021

Treatment of rolling neutrophils with antineutrophil cytoplasmic antibodies causes conversion to firm integrin-mediated adhesion

1 reference

https://api.crossref.org/works/10.1038%2FKI.2010.472

7 January 2021

Membrane proteinase 3 expression and ANCA-induced neutrophil activation

1 reference

https://api.crossref.org/works/10.1038%2FKI.2010.472

7 January 2021

Mediation of endothelial cell damage by serine proteases, but not superoxide, released from antineutrophil cytoplasmic antibody-stimulated neutrophils

1 reference

https://api.crossref.org/works/10.1038%2FKI.2010.472

7 January 2021

Tissue destruction by neutrophils

1 reference

https://api.crossref.org/works/10.1038%2FKI.2010.472

7 January 2021

Free radicals inactivate human neutrophil elastase and its inhibitors with comparable efficiency

1 reference

https://api.crossref.org/works/10.1038%2FKI.2010.472

7 January 2021

Relevance of classic anti-neutrophil cytoplasmic autoantibody (C-ANCA)-mediated inhibition of proteinase 3-alpha 1-antitrypsin complexation to disease activity in Wegener's granulomatosis

1 reference

https://api.crossref.org/works/10.1038%2FKI.2010.472

7 January 2021

Wegener's granulomatosis: anti-proteinase 3 antibodies are potent inductors of human endothelial cell signaling and leakage response

1 reference

https://api.crossref.org/works/10.1038%2FKI.2010.472

7 January 2021

Anti-proteinase-3 (PR3) antibodies (C-ANCA) recognize various targets on the human umbilical vein endothelial cell (HUVEC) membrane

1 reference

https://api.crossref.org/works/10.1038%2FKI.2010.472

7 January 2021

Detection of Fcgamma receptors on human endothelial cells stimulated with cytokines tumour necrosis factor-alpha (TNF-alpha) and interferon-gamma (IFN-gamma).

1 reference

https://api.crossref.org/works/10.1038%2FKI.2010.472

7 January 2021

Up-regulation of adhesion molecule expression in glomerular endothelial cells by anti-myeloperoxidase antibody

1 reference

https://api.crossref.org/works/10.1038%2FKI.2010.472

7 January 2021

Antineutrophil cytoplasmic antibodies stabilize adhesion and promote migration of flowing neutrophils on endothelial cells

1 reference

https://api.crossref.org/works/10.1038%2FKI.2010.472

7 January 2021

ANCA induces beta2 integrin and CXC chemokine-dependent neutrophil-endothelial cell interactions that mimic those of highly cytokine-activated endothelium

1 reference

https://api.crossref.org/works/10.1038%2FKI.2010.472

7 January 2021

Anti-neutrophil cytoplasmic autoantibodies and leukocyte-endothelial interactions: a sticky connection?

1 reference

https://api.crossref.org/works/10.1038%2FKI.2010.472

7 January 2021

Antineutrophil cytoplasmic autoantibodies specific for myeloperoxidase cause glomerulonephritis and vasculitis in mice

1 reference

https://api.crossref.org/works/10.1038%2FKI.2010.472

7 January 2021

Aggravation of anti-myeloperoxidase antibody-induced glomerulonephritis by bacterial lipopolysaccharide: role of tumor necrosis factor-alpha

1 reference

https://api.crossref.org/works/10.1038%2FKI.2010.472

7 January 2021

The role of neutrophils in the induction of glomerulonephritis by anti-myeloperoxidase antibodies

1 reference

https://api.crossref.org/works/10.1038%2FKI.2010.472

7 January 2021

Experimental Autoimmune Vasculitis

1 reference

https://api.crossref.org/works/10.1038%2FKI.2010.472

7 January 2021

Antineutrophil cytoplasmic autoantibodies against the murine homolog of proteinase 3 (Wegener autoantigen) are pathogenic in vivo

1 reference

https://api.crossref.org/works/10.1038%2FKI.2010.472

7 January 2021

Anti-PR3 immune responses induce segmental and necrotizing glomerulonephritis

1 reference

https://api.crossref.org/works/10.1038%2FKI.2010.472

7 January 2021

c-ANCA-induced neutrophil-mediated lung injury: a model of acute Wegener's granulomatosis

1 reference

https://api.crossref.org/works/10.1038%2FKI.2010.472

7 January 2021

Fifty years of antineutrophil cytoplasmic antibodies (ANCA) testing: do we need to revise the international consensus statement on testing and reporting on ANCA?

1 reference

https://api.crossref.org/works/10.1038%2FKI.2010.472

7 January 2021

Association of autoantibodies to myeloperoxidase with different forms of vasculitis

1 reference

https://api.crossref.org/works/10.1038%2FKI.2010.472

7 January 2021

Anti-neutrophil cytoplasmic autoantibodies with specificity for myeloperoxidase in patients with systemic vasculitis and idiopathic necrotizing and crescentic glomerulonephritis

1 reference

https://api.crossref.org/works/10.1038%2FKI.2010.472

7 January 2021

Wegener's granulomatosis autoantibodies identify a novel diisopropylfluorophosphate-binding protein in the lysosomes of normal human neutrophils

1 reference

https://api.crossref.org/works/10.1038%2FKI.2010.472

7 January 2021

Wegener's autoantigen decoded

1 reference

https://api.crossref.org/works/10.1038%2FKI.2010.472

7 January 2021

Molecular mimicry in pauci-immune focal necrotizing glomerulonephritis

1 reference

https://api.crossref.org/works/10.1038%2FKI.2010.472

7 January 2021

Autoimmunity is triggered by cPR-3(105-201), a protein complementary to human autoantigen proteinase-3.

1 reference

https://api.crossref.org/works/10.1038%2FKI.2010.472

7 January 2021

Role of complementary proteins in autoimmunity: an old idea re-emerges with new twists

1 reference

https://api.crossref.org/works/10.1038%2FKI.2010.472

7 January 2021

Association of chronic nasal carriage of Staphylococcus aureus and higher relapse rates in Wegener granulomatosis

1 reference

https://api.crossref.org/works/10.1038%2FKI.2010.472

7 January 2021

Trimethoprim-sulfamethoxazole (co-trimoxazole) for the prevention of relapses of Wegener's granulomatosis. Dutch Co-Trimoxazole Wegener Study Group

1 reference

https://api.crossref.org/works/10.1038%2FKI.2010.472

7 January 2021

Co-trimoxazole and Wegener's granulomatosis: more than a coincidence?

1 reference

https://api.crossref.org/works/10.1038%2FKI.2010.472

7 January 2021

Occurrence of autoantibodies to human leucocyte elastase in Wegener's granulomatosis and other inflammatory disorders

1 reference

https://api.crossref.org/works/10.1038%2FKI.2010.472

7 January 2021

Antineutrophil cytoplasmic antibodies reacting with human neutrophil elastase as a diagnostic marker for cocaine-induced midline destructive lesions but not autoimmune vasculitis.

1 reference

https://api.crossref.org/works/10.1038%2FKI.2010.472

7 January 2021

Vasculitis and antineutrophil cytoplasmic autoantibodies associated with propylthiouracil therapy

1 reference

https://api.crossref.org/works/10.1038%2FKI.2010.472

7 January 2021

Occurrence of antineutrophil cytoplasmic antibodies and associated vasculitis in patients with hyperthyroidism treated with antithyroid drugs: A long-term followup study

1 reference

https://api.crossref.org/works/10.1038%2FKI.2010.472

7 January 2021

Review article: Pathogenic role of complement activation in anti-neutrophil cytoplasmic auto-antibody-associated vasculitis.

1 reference

https://api.crossref.org/works/10.1038%2FKI.2010.472

7 January 2021

Immune complex deposits in ANCA-associated crescentic glomerulonephritis: a study of 126 cases

1 reference

https://api.crossref.org/works/10.1038%2FKI.2010.472

7 January 2021

ANCA-associated crescentic glomerulonephritis with mesangial IgA deposits

1 reference

https://api.crossref.org/works/10.1038%2FKI.2010.472

7 January 2021

Glomerular immune deposits are associated with increased proteinuria in patients with ANCA-associated crescentic nephritis

1 reference

https://api.crossref.org/works/10.1038%2FKI.2010.472

7 January 2021

Neutrophil activation in vitro and in vivo in Wegener's granulomatosis

1 reference

https://api.crossref.org/works/10.1038%2FKI.2010.472

7 January 2021

Histologic and immunohistologic study and clinical presentation of ANCA-associated glomerulonephritis with correlation to ANCA antigen specificity

1 reference

https://api.crossref.org/works/10.1038%2FKI.2010.472

7 January 2021

Detection of immune deposits in skin lesions of patients with Wegener's granulomatosis

1 reference

https://api.crossref.org/works/10.1038%2FKI.2010.472

7 January 2021

Activation of complement in normal serum by hydrogen peroxide and hydrogen peroxide-related oxygen radicals produced by activated neutrophils

1 reference

https://api.crossref.org/works/10.1038%2FKI.2010.472

7 January 2021

Complement activation by myeloperoxidase products released from stimulated human polymorphonuclear leukocytes

1 reference

https://api.crossref.org/works/10.1038%2FKI.2010.472

7 January 2021

Effects of Granulocyte Neutral Proteases on Complement Components

1 reference

https://api.crossref.org/works/10.1038%2FKI.2010.472

7 January 2021

Alternative complement pathway in the pathogenesis of disease mediated by anti-neutrophil cytoplasmic autoantibodies

1 reference

https://api.crossref.org/works/10.1038%2FKI.2010.472

7 January 2021

C5a receptor mediates neutrophil activation and ANCA-induced glomerulonephritis

1 reference

https://api.crossref.org/works/10.1038%2FKI.2010.472

7 January 2021

Inhibition of complement factor C5 protects against anti-myeloperoxidase antibody-mediated glomerulonephritis in mice

1 reference

https://api.crossref.org/works/10.1038%2FKI.2010.472

7 January 2021

Venous thromboembolism in ANCA-associated vasculitis--incidence and risk factors

1 reference

https://api.crossref.org/works/10.1038%2FKI.2010.472

7 January 2021

Complement and coagulation: strangers or partners in crime?

1 reference

https://api.crossref.org/works/10.1038%2FKI.2010.472

7 January 2021

T cells in crescentic glomerulonephritis

1 reference

https://api.crossref.org/works/10.1038%2FKI.2010.472

7 January 2021

Germinal centre-like structures in Wegener's granuloma: the morphological basis for autoimmunity?

1 reference

https://api.crossref.org/works/10.1038%2FKI.2010.472

7 January 2021

T-cells and macrophages in rapidly progressive glomerulonephritis: clinicopathologic correlations

1 reference

https://api.crossref.org/works/10.1038%2FKI.2010.472

7 January 2021

Pulmonary vasculitis (Wegener's granulomatosis). Immunohistochemical study of T and B cell markers

1 reference

https://api.crossref.org/works/10.1038%2FKI.2010.472

7 January 2021

Differential B- and T-cell activation in Wegener's granulomatosis

1 reference

https://api.crossref.org/works/10.1038%2FKI.2010.472

7 January 2021

Serum markers of T cell activation in relapses of Wegener's granulomatosis

1 reference

https://api.crossref.org/works/10.1038%2FKI.2010.472

7 January 2021

Elevated serum levels of soluble interleukin-2 receptor in patients with Wegener's granulomatosis. Association with disease activity

1 reference

https://api.crossref.org/works/10.1038%2FKI.2010.472

7 January 2021

Predominance of IgGl and IgG4 subclasses of anti-neutrophil cytoplasmic autoantibodies (ANCA) in patients with Wegener's granulomatosis and clinically related disorders

1 reference

https://api.crossref.org/works/10.1038%2FKI.2010.472

7 January 2021

Treatment of refractory Wegener's granulomatosis with antithymocyte globulin (ATG): an open study in 15 patients

1 reference

https://api.crossref.org/works/10.1038%2FKI.2010.472

7 January 2021

Abnormalities of CD4 T cell subpopulations in ANCA-associated vasculitis.

1 reference

https://api.crossref.org/works/10.1038%2FKI.2010.472

7 January 2021

Persistent T-cell activation and clinical correlations in patients with ANCA-associated systemic vasculitis

1 reference

https://api.crossref.org/works/10.1038%2FKI.2010.472

7 January 2021

CD4+CD25+ T-cell populations expressing CD134 and GITR are associated with disease activity in patients with Wegener's granulomatosis.

1 reference

https://api.crossref.org/works/10.1038%2FKI.2010.472

7 January 2021

Urinary CD4+ effector memory T cells reflect renal disease activity in antineutrophil cytoplasmic antibody-associated vasculitis

1 reference

https://api.crossref.org/works/10.1038%2FKI.2010.472

7 January 2021

Effector memory T cells as driving force of granuloma formation and autoimmunity in Wegener's granulomatosis.

1 reference

https://api.crossref.org/works/10.1038%2FKI.2010.472

7 January 2021

T(H)-17 cells in the circle of immunity and autoimmunity

1 reference

https://api.crossref.org/works/10.1038%2FKI.2010.472

7 January 2021

Skewed distribution of Th17 lymphocytes in patients with Wegener's granulomatosis in remission

1 reference

https://api.crossref.org/works/10.1038%2FKI.2010.472

7 January 2021

Serum IL-17 and IL-23 levels and autoantigen-specific Th17 cells are elevated in patients with ANCA-associated vasculitis

1 reference

https://api.crossref.org/works/10.1038%2FKI.2010.472

7 January 2021

CD45RC isoform expression identifies functionally distinct T cell subsets differentially distributed between healthy individuals and AAV patients

1 reference

https://api.crossref.org/works/10.1038%2FKI.2010.472

7 January 2021

Human regulatory T cells: role in autoimmune disease and therapeutic opportunities

1 reference

https://api.crossref.org/works/10.1038%2FKI.2010.472

7 January 2021

Persistent expansion of CD4+ effector memory T cells in Wegener's granulomatosis.

1 reference

https://api.crossref.org/works/10.1038%2FKI.2010.472

7 January 2021

Functional defect of circulating regulatory CD4+ T cells in patients with Wegener's granulomatosis in remission

1 reference

https://api.crossref.org/works/10.1038%2FKI.2010.472

7 January 2021

Patients with Wegener's granulomatosis demonstrate a relative deficiency and functional impairment of T-regulatory cells

1 reference

https://api.crossref.org/works/10.1038%2FKI.2010.472

7 January 2021

Lymphoid neogenesis in chronic inflammatory diseases.

1 reference

https://api.crossref.org/works/10.1038%2FKI.2010.472

7 January 2021

Is PR3-ANCA formation initiated in Wegener's granulomatosis lesions? Granulomas as potential lymphoid tissue maintaining autoantibody production

1 reference

https://api.crossref.org/works/10.1038%2FKI.2010.472

7 January 2021

Wegener autoantigen induces maturation of dendritic cells and licenses them for Th1 priming via the protease-activated receptor-2 pathway

1 reference

https://api.crossref.org/works/10.1038%2FKI.2010.472

7 January 2021

Expansion of circulating NKG2D+ effector memory T-cells and expression of NKG2D-ligand MIC in granulomaous lesions in Wegener's granulomatosis.

1 reference

https://api.crossref.org/works/10.1038%2FKI.2010.472

7 January 2021

B lymphocyte maturation in Wegener's granulomatosis: a comparative analysis of VH genes from endonasal lesions

1 reference

https://api.crossref.org/works/10.1038%2FKI.2010.472

7 January 2021

Compartment specific expression of dendritic cell markers in human glomerulonephritis

1 reference

https://api.crossref.org/works/10.1038%2FKI.2010.472

7 January 2021

Dendritic cells in renal biopsies of patients with ANCA-associated vasculitis.

1 reference

https://api.crossref.org/works/10.1038%2FKI.2010.472

7 January 2021

Analysis and classification of B-cell infiltrates in lupus and ANCA-associated nephritis

1 reference

https://api.crossref.org/works/10.1038%2FKI.2010.472

7 January 2021

Renal dendritic cells stimulate IL-10 production and attenuate nephrotoxic nephritis

1 reference

https://api.crossref.org/works/10.1038%2FKI.2010.472

7 January 2021

Immature, semi-mature and fully mature dendritic cells: which signals induce tolerance or immunity?

1 reference

https://api.crossref.org/works/10.1038%2FKI.2010.472

7 January 2021

Netting neutrophils in autoimmune small-vessel vasculitis

1 reference

https://api.crossref.org/works/10.1038%2FKI.2010.472

7 January 2021

Neutrophil extracellular traps kill bacteria

1 reference

https://api.crossref.org/works/10.1038%2FKI.2010.472

7 January 2021

Chromatin-IgG complexes activate B cells by dual engagement of IgM and Toll-like receptors

1 reference

https://api.crossref.org/works/10.1038%2FKI.2010.472

7 January 2021

Dysfunctional CD4+,CD25+ regulatory T cells in untreated active systemic lupus erythematosus secondary to interferon-alpha-producing antigen-presenting cells

1 reference

https://api.crossref.org/works/10.1038%2FKI.2010.472

7 January 2021

NETs: a new strategy for using old weapons

1 reference

https://api.crossref.org/works/10.1038%2FKI.2010.472

7 January 2021

Wegener's Granulomatosis: Prospective Clinical and Therapeutic Experience With 85 Patients for 21 Years

1 reference

https://api.crossref.org/works/10.1038%2FKI.2010.472

7 January 2021

Giant-cell granuloma of the respiratory tract (Wegener's granulomatosis)

1 reference

https://api.crossref.org/works/10.1038%2FKI.2010.472

7 January 2021

Cyclophosphamide and cancer: golden anniversary

1 reference

https://api.crossref.org/works/10.1038%2FKI.2010.472

7 January 2021

Rituximab versus cyclophosphamide in ANCA-associated renal vasculitis

1 reference

https://api.crossref.org/works/10.1038%2FKI.2010.472

7 January 2021

Randomized trial of plasma exchange or high-dosage methylprednisolone as adjunctive therapy for severe renal vasculitis

1 reference

https://api.crossref.org/works/10.1038%2FKI.2010.472

7 January 2021

Rituximab versus cyclophosphamide for ANCA-associated vasculitis

1 reference

https://api.crossref.org/works/10.1038%2FKI.2010.472

7 January 2021

Long-term follow-up of relapsing/refractory anti-neutrophil cytoplasm antibody associated vasculitis treated with the lymphocyte depleting antibody alemtuzumab (CAMPATH-1H).

1 reference

https://api.crossref.org/works/10.1038%2FKI.2010.472

7 January 2021

EULAR recommendations for the management of primary small and medium vessel vasculitis.

1 reference

https://api.crossref.org/works/10.1038%2FKI.2010.472

7 January 2021

Pulse versus daily oral cyclophosphamide for induction of remission in antineutrophil cytoplasmic antibody-associated vasculitis: a randomized trial.

1 reference

https://api.crossref.org/works/10.1038%2FKI.2010.472

7 January 2021

A randomized trial of maintenance therapy for vasculitis associated with antineutrophil cytoplasmic autoantibodies

1 reference

https://api.crossref.org/works/10.1038%2FKI.2010.472

7 January 2021

Interventions for renal vasculitis in adults. A systematic review

1 reference

https://api.crossref.org/works/10.1038%2FKI.2010.472

7 January 2021

Randomized trial of cyclophosphamide versus methotrexate for induction of remission in early systemic antineutrophil cytoplasmic antibody-associated vasculitis

1 reference

https://api.crossref.org/works/10.1038%2FKI.2010.472

7 January 2021

Mycophenolate mofetil in anti-neutrophil cytoplasm antibodies-associated systemic vasculitis

1 reference

https://api.crossref.org/works/10.1038%2FKI.2010.472

7 January 2021

Induction of remission in active anti-neutrophil cytoplasmic antibody-associated vasculitis with mycophenolate mofetil in patients who cannot be treated with cyclophosphamide

1 reference

https://api.crossref.org/works/10.1038%2FKI.2010.472

7 January 2021

Mycophenolate mofetil versus cyclophosphamide for inducing remission of ANCA vasculitis with moderate renal involvement

1 reference

https://api.crossref.org/works/10.1038%2FKI.2010.472

7 January 2021

Etanercept plus standard therapy for Wegener's granulomatosis

1 reference

https://api.crossref.org/works/10.1038%2FKI.2010.472

7 January 2021

Solid malignancies among patients in the Wegener's Granulomatosis Etanercept Trial

1 reference

https://api.crossref.org/works/10.1038%2FKI.2010.472

7 January 2021

Prospective study of TNFalpha blockade with adalimumab in ANCA-associated systemic vasculitis with renal involvement

1 reference

https://api.crossref.org/works/10.1038%2FKI.2010.472

7 January 2021

Treatment of Churg-Strauss syndrome without poor-prognosis factors: A multicenter, prospective, randomized, open-label study of seventy-two patients

1 reference

https://api.crossref.org/works/10.1038%2FKI.2010.472

7 January 2021

Intravenous immunoglobulin for ANCA-associated systemic vasculitis with persistent disease activity

1 reference

https://api.crossref.org/works/10.1038%2FKI.2010.472

7 January 2021

15-Deoxyspergualin in patients with refractory ANCA-associated systemic vasculitis: a six-month open-label trial to evaluate safety and efficacy

1 reference

https://api.crossref.org/works/10.1038%2FKI.2010.472

7 January 2021

Deoxyspergualin in relapsing and refractory Wegener's granulomatosis

1 reference

https://api.crossref.org/works/10.1038%2FKI.2010.472

7 January 2021

Mixed lymphohematopoietic chimerism and response in Wegener's granulomatosis

1 reference

https://api.crossref.org/works/10.1038%2FKI.2010.472

7 January 2021

A multicenter survey of rituximab therapy for refractory antineutrophil cytoplasmic antibody-associated vasculitis.

1 reference

https://api.crossref.org/works/10.1038%2FKI.2010.472

7 January 2021

B-cell depletion with rituximab for refractory head and neck Wegener's granulomatosis: a cohort study

1 reference

https://api.crossref.org/works/10.1038%2FKI.2010.472

7 January 2021

Omalizumab administration in Churg-Strauss syndrome

1 reference

https://api.crossref.org/works/10.1038%2FKI.2010.472

7 January 2021

Sustained response to mepolizumab in refractory Churg-Strauss syndrome

1 reference

https://api.crossref.org/works/10.1038%2FKI.2010.472

7 January 2021

Outcomes from studies of antineutrophil cytoplasm antibody associated vasculitis: a systematic review by the European League Against Rheumatism systemic vasculitis task force

1 reference

https://api.crossref.org/works/10.1038%2FKI.2010.472

7 January 2021

Predictors of treatment resistance and relapse in antineutrophil cytoplasmic antibody-associated small-vessel vasculitis: comparison of two independent cohorts

1 reference

https://api.crossref.org/works/10.1038%2FKI.2010.472

7 January 2021

Mycophenolate mofetil for remission maintenance in the treatment of Wegener's granulomatosis

1 reference

https://api.crossref.org/works/10.1038%2FKI.2010.472

7 January 2021

Mycophenolate mofetil vs azathioprine for remission maintenance in antineutrophil cytoplasmic antibody-associated vasculitis: a randomized controlled trial.

1 reference

https://api.crossref.org/works/10.1038%2FKI.2010.472

7 January 2021

Azathioprine or methotrexate maintenance for ANCA-associated vasculitis

1 reference

https://api.crossref.org/works/10.1038%2FKI.2010.472

7 January 2021

Elevated relapse rate under oral methotrexate versus leflunomide for maintenance of remission in Wegener's granulomatosis

1 reference

https://api.crossref.org/works/10.1038%2FKI.2010.472

7 January 2021

Effects of duration of glucocorticoid therapy on relapse rate in antineutrophil cytoplasmic antibody-associated vasculitis: A meta-analysis

1 reference

https://api.crossref.org/works/10.1038%2FKI.2010.472

7 January 2021

Mepolizumab as a steroid-sparing treatment option in patients with Churg-Strauss syndrome

1 reference

https://api.crossref.org/works/10.1038%2FKI.2010.472

7 January 2021

EULAR recommendations for conducting clinical studies and/or clinical trials in systemic vasculitis: focus on anti-neutrophil cytoplasm antibody-associated vasculitis

1 reference

https://api.crossref.org/works/10.1038%2FKI.2010.472

7 January 2021

Positive classic antineutrophil cytoplasmic antibody (C-ANCA) titer at switch to azathioprine therapy associated with relapse in proteinase 3-related vasculitis

1 reference

https://api.crossref.org/works/10.1038%2FKI.2010.472

7 January 2021

Prevention of relapses in Wegener's granulomatosis by treatment based on antineutrophil cytoplasmic antibody titre

1 reference

https://api.crossref.org/works/10.1038%2FKI.2010.472

7 January 2021

ANCA Testing in Monitoring the Activity of the Disease

1 reference

https://api.crossref.org/works/10.1038%2FKI.2010.472

7 January 2021

Targeting B lymphocytes as therapy for ANCA-associated vasculitis

1 reference

https://api.crossref.org/works/10.1038%2FKI.2010.472

7 January 2021

CD4+CD25+ regulatory T cells in transplantation: progress, challenges and prospects

1 reference

https://api.crossref.org/works/10.1038%2FKI.2010.472

7 January 2021

Immunological monitoring of renal transplant recipients to predict acute allograft rejection following the discontinuation of tacrolimus

1 reference

https://api.crossref.org/works/10.1038%2FKI.2010.472

7 January 2021

Immunologic, clinical, and radiologic status 14 months after cessation of natalizumab therapy

1 reference

https://api.crossref.org/works/10.1038%2FKI.2010.472

7 January 2021

Iatrogenic immunosuppression with biologics in MS: expecting the unexpected?

1 reference

https://api.crossref.org/works/10.1038%2FKI.2010.472

7 January 2021

Human CD25highFoxp3pos regulatory T cells differentiate into IL-17-producing cells

1 reference

https://api.crossref.org/works/10.1038%2FKI.2010.472

7 January 2021

Costimulation blockade in autoimmunity and transplantation

1 reference

https://api.crossref.org/works/10.1038%2FKI.2010.472

7 January 2021

From bone marrow to the arterial wall: the ongoing tale of endothelial progenitor cells.

1 reference

https://api.crossref.org/works/10.1038%2FKI.2010.472

7 January 2021

Increased incidence of cardiovascular events in patients with antineutrophil cytoplasmic antibody-associated vasculitides: a matched-pair cohort study

1 reference

https://api.crossref.org/works/10.1038%2FKI.2010.472

7 January 2021

Reduced number of endothelial progenitor cells is predictive of early relapse in anti-neutrophil cytoplasmic antibody-associated vasculitis.

1 reference

https://api.crossref.org/works/10.1038%2FKI.2010.472

7 January 2021

Translational mini-review series on immunology of vascular disease: accelerated atherosclerosis in vasculitis

1 reference

https://api.crossref.org/works/10.1038%2FKI.2010.472

7 January 2021

BAFF is elevated in serum of patients with Wegener's granulomatosis

1 reference

https://api.crossref.org/works/10.1038%2FKI.2010.472

7 January 2021

Anti-CD11b monoclonal antibody improves myocardial function after six hours of hypothermic storage

1 reference

https://api.crossref.org/works/10.1038%2FKI.2010.472

7 January 2021

Interleukin 2 receptor antagonists for kidney transplant recipients

1 reference

https://api.crossref.org/works/10.1038%2FKI.2010.472

7 January 2021

Daclizumab for relapsing remitting multiple sclerosis

1 reference

https://api.crossref.org/works/10.1038%2FKI.2010.472

7 January 2021

Staphylococcal toxic-shock-syndrome-toxin-1 as a risk factor for disease relapse in Wegener's granulomatosis

1 reference

https://api.crossref.org/works/10.1038%2FKI.2010.472

7 January 2021

Identifiers

DOI

10.1038/KI.2010.472

1 reference

23 August 2017

1 reference